Sandoz’s Zessly (infliximab) Receives EU Approval for Gastroenterological, Rheumatological And Dermatological Diseases

Shots:

• The approval is based on non-inferiority and P-III REFLECTIONS B537-02 study results assessing Zessly vs reference drug and demonstrated meeting 1EPs with safety, efficacy and quality
• Zessly is 3^rd EC approval in 12 mos. and 6^th biosimilar approval for Sandoz
• Zessly (infliximab) is a mAb, blocks the action of tumor necrosis factor (TNF)-alpha in patients with autoimmune disorders

Click here read full press release/ article | Ref: Sandoz | Image: Princeton Forrestal Center